No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Zarxio is a biologic drug used to treat immune disorders, such as neutropenia, a condition in which the body does not produce enough white blood cells. Zarxio is a biosimilar to Neupogen, a drug developed by Amgen, and is the first biosimilar approved by the U.S. Food and Drug Administration (FDA). Zarxio is used to reduce the duration and severity of neutropenia in patients with certain types of cancer who are receiving chemotherapy. It is also used to reduce the risk of infection in patients with severe chronic neutropenia.
The Zarxio market is highly competitive, with several companies offering biosimilars of Neupogen. These companies include Sandoz, Pfizer, Celltrion, Hospira, and Mylan. Each company has its own unique approach to the development and marketing of Zarxio, and they all compete for market share. Show Less Read more
